JP2009509553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509553A5 JP2009509553A5 JP2008533917A JP2008533917A JP2009509553A5 JP 2009509553 A5 JP2009509553 A5 JP 2009509553A5 JP 2008533917 A JP2008533917 A JP 2008533917A JP 2008533917 A JP2008533917 A JP 2008533917A JP 2009509553 A5 JP2009509553 A5 JP 2009509553A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- fusion polypeptide
- mmp
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72449805P | 2005-10-07 | 2005-10-07 | |
| US60/724,498 | 2005-10-07 | ||
| PCT/EP2006/009536 WO2007042169A2 (en) | 2005-10-07 | 2006-10-03 | Matrix metalloproteinase 11 vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009509553A JP2009509553A (ja) | 2009-03-12 |
| JP2009509553A5 true JP2009509553A5 (enExample) | 2009-10-22 |
| JP5361386B2 JP5361386B2 (ja) | 2013-12-04 |
Family
ID=37451271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533917A Expired - Fee Related JP5361386B2 (ja) | 2005-10-07 | 2006-10-03 | マトリックスメタロプロテイナーゼ１１ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8106176B2 (enExample) |
| EP (1) | EP1934246B8 (enExample) |
| JP (1) | JP5361386B2 (enExample) |
| CN (1) | CN101365715B (enExample) |
| AT (1) | ATE521629T1 (enExample) |
| AU (1) | AU2006301582B2 (enExample) |
| CA (1) | CA2623531C (enExample) |
| ES (1) | ES2370040T3 (enExample) |
| WO (1) | WO2007042169A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2342334A4 (en) * | 2008-09-29 | 2012-03-14 | Univ Pennsylvania | VACCINES DIRECTED TO TUMOR VESSEL MARKERS |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| CA2770822C (en) * | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| EP2496700B1 (en) * | 2009-11-04 | 2017-03-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| EP3069785A1 (en) | 2011-10-25 | 2016-09-21 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
| CN105143456A (zh) | 2013-03-15 | 2015-12-09 | 不列颠哥伦比亚大学 | 用于转染的脂质纳米粒子和相关方法 |
| DK3388075T5 (da) | 2015-03-27 | 2024-09-23 | Immatics Biotechnologies Gmbh | Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| WO2018156106A1 (en) * | 2017-02-22 | 2018-08-30 | Ding Enyu | An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes |
| WO2021071976A1 (en) * | 2019-10-08 | 2021-04-15 | Exhaura, Ltd. | Compositions and methods for ocular therapy |
| WO2022220603A1 (ko) | 2021-04-16 | 2022-10-20 | 고려대학교 산학협력단 | 코로나-19 바이러스 표적 인간 항체 |
| GB202117583D0 (en) * | 2021-12-06 | 2022-01-19 | Cambridge Entpr Ltd | Protein expression |
| CN116590263A (zh) * | 2023-07-02 | 2023-08-15 | 广州庆毅生物医药科技有限公司 | 一种重组蛋白、单克隆抗体及其检测试剂盒和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL78775A (en) | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
| GB9112553D0 (en) | 1991-06-11 | 1991-07-31 | Wellcome Found | Fusion proteins |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JP2000511190A (ja) * | 1996-05-23 | 2000-08-29 | ゾーマ コーポレイション | 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途 |
| US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| WO2000065076A2 (en) | 1999-04-26 | 2000-11-02 | K.U. Leuven Research & Development | Synthetic gene for expressing active retroviral protein in eukaryotes |
| IL149009A0 (en) | 1999-10-08 | 2002-11-10 | Active Biotech Ab | Ab5 toxin b subunt mutants with altered chemical conjugation characteristics |
| GB9930768D0 (en) * | 1999-12-29 | 2000-02-16 | Pfizer Ltd | Composition |
| EP1320621A4 (en) | 2000-09-15 | 2005-11-23 | Merck & Co Inc | IMPROVED ADENOVIRAL VACCINES OF THE FIRST GENERATION FOR THE EXPRESSION OF CODON-OPTIMIZED HIV-1 GAG, POL, NEF AND MODIFICATIONS (25.03.02) |
| US20040110152A1 (en) | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of matrix metalloproteinase 11 expression |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| SG146662A1 (en) * | 2003-10-10 | 2008-10-30 | Powderject Vaccines Inc | Method |
| ATE555127T1 (de) | 2004-02-11 | 2012-05-15 | Angeletti P Ist Richerche Bio | Fusionsproteine des karzinomembryonalen antigens und deren verwendungen |
-
2006
- 2006-10-03 JP JP2008533917A patent/JP5361386B2/ja not_active Expired - Fee Related
- 2006-10-03 AU AU2006301582A patent/AU2006301582B2/en not_active Ceased
- 2006-10-03 US US12/083,031 patent/US8106176B2/en active Active
- 2006-10-03 EP EP06792355A patent/EP1934246B8/en active Active
- 2006-10-03 ES ES06792355T patent/ES2370040T3/es active Active
- 2006-10-03 CN CN2006800370642A patent/CN101365715B/zh not_active Expired - Fee Related
- 2006-10-03 WO PCT/EP2006/009536 patent/WO2007042169A2/en not_active Ceased
- 2006-10-03 AT AT06792355T patent/ATE521629T1/de not_active IP Right Cessation
- 2006-10-03 CA CA2623531A patent/CA2623531C/en not_active Expired - Fee Related
-
2011
- 2011-12-21 US US13/332,580 patent/US8492522B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509553A5 (enExample) | ||
| JP2008099688A5 (enExample) | ||
| JP2011224002A5 (enExample) | ||
| CN103060301A (zh) | 乳酸片球菌的n-乙酰神经氨酸醛缩酶及其基因与应用 | |
| CN104818265B (zh) | 一种降解尿素和氨基甲酸乙酯的耐乙醇双功能酶及其应用 | |
| CA2555013A1 (en) | Carcinoembryonic antigen fusions and uses thereof | |
| CA3057252A1 (en) | Expression and large-scale production of peptides | |
| CN101991844B (zh) | 一种迟缓爱德华氏菌重组亚单位疫苗及其应用 | |
| CN109988802A (zh) | 一种高效分泌表达人源fgf21蛋白的表达盒及其应用 | |
| JP2004532037A5 (enExample) | ||
| CN103451216B (zh) | 一种氨基甲酸乙酯水解酶基因及其编码的蛋白质和应用 | |
| CN101921800A (zh) | 启动因子作为融合标签的大肠杆菌蛋白表达载体及其构建方法和应用 | |
| Khalili et al. | High‐level expression and purification of soluble bioactive recombinant human heparin‐binding epidermal growth factor in Escherichia coli | |
| JP2009507474A5 (enExample) | ||
| RU2453604C1 (ru) | Гибридный белок (варианты), штамм бактерий escherichia coli - продуцент гибридного белка (варианты) и способ получения безметионинового интерферона альфа-2 человека | |
| ES2537701T3 (es) | Un método de hidrólisis de péptidos, uso de una composición como agente bacteriostático y bactericida y los usos de la forma activa de LytM de S. aureus | |
| CN100575492C (zh) | 一种编码双齿围沙蚕蛋白酶的cDNA序列及其氨基酸序列 | |
| CN107164350B (zh) | 一种吡嗪酰胺水解酶与其编码基因和应用 | |
| WO2003031594A3 (en) | Nucleotide and amino acid sequences relating to respiratory diseases and obesity | |
| KR101837636B1 (ko) | 코리네박테리움 재조합 균주를 이용한 아스파라기나제의 분비생산 방법 | |
| CN103305450B (zh) | 一种大肠杆菌表达菌株及用其生产n-乙酰-d-神经氨酸的方法 | |
| WO2009038841A3 (en) | Portable, temperature and chemically inducible expression vector for high cell density expression of heterologous genes in escherichia coli | |
| CN103755799B (zh) | 一种具有抗肿瘤作用的肿瘤抑素30肽及其制备方法和应用 | |
| CN105399808A (zh) | 一种许氏平鮋免疫增强蛋白hmgb1基因及编码蛋白和应用 | |
| JP2004536589A5 (enExample) |